Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

EMA sees approval numbers rise in 2018

EMA sees approval numbers rise in 2018

From these, 21 were orphan medicines (exactly 50%) and three were advanced therapy medicinal products – Novartis’ Kymriah and Gilead/Kite’s Yescarta CAR-T therapies, plus Spark’s Luxturna, co-marketed

Latest news

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    oncology. Both companies have been talked about as possible M&A instigators or targets for the last few years, so the tie-up hasn’t come as a complete surprise, nevertheless ... Two of Celgene’s most promising candidates are in BCMA-targeting CAR-T

  • Dragonfly signs Celgene as partner for NK cell platform Dragonfly signs Celgene as partner for NK cell platform

    That differentiates TriNKETs from other immuno-oncology approaches such as checkpoint inhibitors and CAR-T therapies which work through the adaptive immune response only, says the Cambridge, Masachusetts-based biotech. ... Foremost among these was its

  • Industry frustrated by late warning on 'no deal' Brexit disruption Industry frustrated by late warning on 'no deal' Brexit disruption

    Health secretary Matt Hancock has written to pharma companies today, warning that the government’s previous advice that they build up six weeks’ worth of medicines stockpiles won’t be enough, ... One reason stockpiling isn’t a complete solution

  • CAR-Ts take centre stage as ASH18 comes to a close CAR-Ts take centre stage as ASH18 comes to a close

    The last few days of the American Society of Haematology (ASH) annual congress saw a series of new trials on CAR-T therapies that reinforce the emerging role of this type ... There was plenty more activity on the anti-BCMA CAR-T front at ASH.

  • ASH18: CAR-T and drugs give new options for multiple myeloma ASH18: CAR-T and drugs give new options for multiple myeloma

    San Diego congress showcasing data in important haematology markets. Celgene and Bluebird Bio’s anti-BCMA CAR-T bb21217 is effective in patients with very advanced multiple myeloma, and crucially seems ... There will be plenty of additional news on

More from news
Approximately 3 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    This low rate of growth, combined with new price controls introduced by NHS England on new innovative medicines, means the pharma sector isn’t jumping for joy over the deal. ... of this include recent deals on CAR-T therapies, plus a new expansion in

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The challenges ahead are to improve the

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

  • Download our infographic: Addressing the biggest challenges for rare disease communities

    Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’t make the link between common symptoms and a rare disease. ... year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene

  • Ashfield

    Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies. ... Whether we’re buying something as simple as a toaster or as expensive as a new car, we’ve all come to expect fantastic service at

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics